foxo4-dri peptide senolytic human trial FOXO4-DRI: Status, Cancer Research & Data Development of a novel senolytic

Injury recovery Explored in preclinical research on recovery from acute injury and overuse strain

GHK-Cu is a complex of copper and glycyl-l-histidyl-l-lysine (GHK), a peptide present in human plasma, saliva, and urine that decreases in concentration as we age

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Seguin and colleagues reported that systemic administration of TNF reduced NSC proliferation in the dentate gyrus [101]

A counteracting agent may be the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, an anti-ulcer peptide per-orally active (12-15) that may also affect many central disturbances (16-23), efficient in inflammatory bowel disease trials (PL 14736) (24, 25) and various wound treatment (26-28), no toxicity reported (12, 13, 24, 25)) which showed various hepatoprotective effects (29-31)